David Planchard
Mar 24, 2025, 09:05
David Planchard: Neoadjuvant and adjuvant treatments for lung cancer to optimize patients’ survival
David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, posted on LinkedIn:
“So many questions about neoadjuvant/adjuvant treatments (IO, TKI, ADC…) for lung cancer and the use of biomarkers (MRD, NGS, pCR…) to optimize our treatments and our patients’ survival.
Panel discussion here in NY!”
Read more posts featuring Lung Cancer at OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 15:01
May 10, 2025, 15:01
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57